子宫肌瘤药物市场－全球产业规模、份额、趋势、机会及预测（依药物类别、类型、最终用户、地区和竞争格局划分，2021-2031年）

全球子宫肌瘤治疗市场预计将从 2025 年的 49.5 亿美元成长到 2031 年的 64.2 亿美元，年复合成长率为 4.43%。

该市场涵盖促性腺激素分泌释放激素 (GnRH) 拮抗剂和促效剂等药物，用于缓解月经过多等症状和缩小肿瘤。其成长主要受患者偏好转变的驱动，患者倾向于选择非手术、保留子宫的治疗方法，以及口服药物日益普及，因为与侵入性手术相比，口服药物更便捷。根据美国女性健康研究协会 (Women's Health Research Association) 2025 年的预测，美国约有 2,600 万名女性患有子宫肌瘤，这构成了一项重大的疾病负担，亟需有效的药物治疗方案。

儘管具有这种潜力，但由于新型品牌疗法的高昂成本以及长期用药带来的安全隐患，市场成长仍面临许多重大障碍。例如，长期荷尔蒙抑制治疗可能导致骨骼密度下降等风险，从而限制治疗的耐受性持续时间，并增加治疗方案的复杂性。此外，昂贵的新药还需满足严格的报销要求，这些因素阻碍了患者获得治疗，有效抑制了先进药物疗法的广泛应用。

市场驱动因素

新型口服促性腺激素分泌释放激素 (GnRH) 拮抗剂的商业性化上市和广泛应用，大大推动了市场成长。这些药物提供了有效且非侵入性的治疗选择。例如，Relugolix)和林扎戈利 (linzagolix) 等治疗方法为女性提供了一种便捷的口服途径来控制月经过多等症状，避免了手术带来的恢復时间和风险。这种强劲的需求也体现在主要产业相关人员的财务表现中。例如，吉瑞製药 (Gedeon Richter) 于 2025 年 11 月发布的「2025 年第一至第三季财务报告」显示，其子宫肌瘤药物 Lyeco 的销售额同比增长 97.3%，凸显了这些口服拮抗剂作为一线治疗药物的迅速普及。

同时，强大的临床研发管线和对女性健康研究与开发的持续投入，正推动下一代治疗方法的研发。投资者和製药公司都意识到该领域存在着巨大的未满足需求，因此加大了资金投入，以拓展手术和荷尔蒙避孕之外的治疗选择。硅谷银行于2025年4月发布的《2025年女性健康创新报告》显示，预计2024年，该领域的创业投资将达到26亿美元，显示市场对未来的成长充满信心。这些资金对于应对子宫肌瘤的广泛影响至关重要。女性健康研究协会指出，到2025年，高达80%的女性在50岁之前会罹患子宫肌瘤，这意味着大规模的患者族群需要持续的治疗方法创新。

市场挑战

全球子宫肌瘤治疗市场成长的主要障碍是长期用药相关的安全隐患，尤其是可能导致骨骼密度下降的风险。由于促性腺激素释放激素（GnRH）拮抗剂等药物通常会将雌激素抑製到威胁骨骼健康的水平，监管机构通常会限制治疗持续时间。这种临床限制使得这些药物无法作为长期慢性病治疗方案，从而大幅降低了每位患者的收入潜力，并阻碍了治疗的连续性。因此，患者往往被迫停止有效的药物治疗，转而选择手术治疗，导致药物销售量持续下降。

此外，这种安全性使得高成本品牌疗法的经济效益难以论证。保险公司和支付者采用严格的报销标准，并且由于使用限制，不愿承保只能暂时缓解症状的昂贵药物，从而阻碍了此类药物的广泛应用。这些限制凸显了疾病持续带来的经济负担。根据美国女性健康研究协会 (SWHR) 2025 年的估计，子宫肌瘤患者的劳动生产力损失总计达 172 亿美元。这项数据强调了市场无法提供安全、长期有效的药物疗法这一现实，造成了巨大的临床和经济缺口，最终阻碍了整个领域的发展。

市场趋势

联合疗法的引入正在从根本上重塑治疗格局，这些疗法能够减轻低雌激素副作用，克服传统荷尔蒙疗法的安全性限制。虽然促性腺激素分泌释放激素 (GnRH) 拮抗剂能有效缩小子宫肌瘤，但由于骨骼密度下降的风险，长期用药历来都是一个挑战。为了解决这个问题，研发人员正在将固定剂量方案商业化，这些方案通常包含醋酸炔诺酮和雌二醇“替代疗法”，旨在将雌激素水平维持在既不影响疗效又能保护骨骼健康的范围内。这项进展使得治疗持续时间得以延长，从而提高了其在慢性病管理中的应用。根据住友製药于 2025 年 5 月发布的“截至 2025 年 3 月的财年总结”，联合治疗Myfenvly 在 2024 财年的销售额同比增长了 32%。

同时，随着医疗服务提供者和患者越来越倾向于避免子宫切除等侵入性手术，第一线药物治疗的模式转移正在加速。这项转变的驱动力在于有效口服药物的广泛应用，为希望避免併发症和恢復期的女性提供了一种「保留子宫」的选择。临床指引也日益倾向于第一线药物治疗，而非「后续观察」或术前治疗，从而扩大了目标患者群体。这种结构性转变也体现在产业绩效中。例如，吉瑞製药（Gedeon Richter）于2025年2月发布的《2024财年第四季财务报告》预测，其女性健康部门2024年的营收将成长12%，这显示药物治疗在标准治疗中的作用日益增强。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球子宫肌瘤治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（促性腺激素分泌释放激素 (GnRH)促效剂、促性腺激素分泌释放激素 (GnRH) 拮抗剂、黄体素释放子宫内避孕器 (IUD) 和避孕药、非荷尔蒙药物、其他）
  • 依类型（浆膜下肌瘤、肌壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
  • 依最终用户（医院药局、零售药局、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美子宫肌瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲子宫肌瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区子宫肌瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲子宫肌瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美子宫肌瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球子宫肌瘤治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Myovant Sciences Ltd
• Pfizer Inc
• Abbvie Inc
• Ferring BV
• AstraZeneca
• Bayer AG
• Amring Pharmaceuticals Inc
• Watson Pharma Pvt Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Uterine Fibroid Treatment Drugs Market is projected to expand from a valuation of USD 4.95 Billion in 2025 to USD 6.42 Billion by 2031, reflecting a compound annual growth rate of 4.43%. This market encompasses pharmaceutical agents, such as Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists, which are utilized to alleviate symptoms like menorrhagia and decrease tumor size. Growth is largely propelled by a shifting patient preference toward uterine-sparing, non-surgical interventions and the increasing accessibility of oral treatments that provide greater convenience compared to invasive procedures. As highlighted by the Society for Women's Health Research in 2025, approximately 26 million women in the United States are affected by uterine fibroids, emphasizing the significant burden of disease that demands effective pharmacological management solutions.

Despite this potential, market growth faces substantial obstacles due to the elevated costs of new branded therapies and safety issues related to their long-term administration. Risks such as reduced bone mineral density associated with extended hormonal suppression can limit the permissible duration of therapy and add complexity to treatment plans. When combined with strict reimbursement requirements for high-priced novel drugs, these clinical restrictions create hurdles for patient access and effectively hinder the broader adoption of advanced pharmaceutical remedies.

Market Driver

The market is being significantly advanced by the commercial launch and widespread acceptance of novel oral Gonadotropin-Releasing Hormone (GnRH) antagonists, which offer effective, non-invasive treatment options. Therapies such as relugolix and linzagolix provide women with a convenient daily oral routine to control symptoms like heavy menstrual bleeding, eliminating the recovery time and risks inherent to surgical procedures. This strong demand is reflected in the financial results of major industry stakeholders; for example, Gedeon Richter's 'Q1-Q3 2025 Earnings Report' from November 2025 indicated that sales of the uterine fibroid drug Ryeqo increased by 97.3% year-over-year, demonstrating the rapid uptake of these oral antagonists as a preferred first-line therapy.

In parallel, a strong clinical pipeline and continuous investment in women's health research and development are driving the creation of next-generation treatments. Both investors and pharmaceutical firms are acknowledging the significant unmet needs in this field, resulting in increased funding to expand options beyond surgery and hormonal contraceptives. According to the 'Innovation in Women's Health 2025' report by Silicon Valley Bank in April 2025, venture capital investment in the sector hit $2.6 billion in 2024, indicating robust confidence in future growth. This capital is essential for addressing the condition's broad impact; the Society for Women's Health Research noted in 2025 that uterine fibroids affect up to 80% of women by age 50, establishing a large demographic that requires ongoing therapeutic innovation.

Market Challenge

A major impediment to the growth of the Global Uterine Fibroid Treatment Drugs Market is safety apprehension regarding long-term use, particularly the potential for reduced bone mineral density. Since pharmaceutical agents such as GnRH antagonists frequently suppress estrogen to levels that may endanger bone health, regulatory bodies often impose limits on how long therapy can continue. This clinical restriction prevents these drugs from serving as long-term chronic care solutions, effectively limiting revenue potential per patient and interrupting the continuity of care, which often forces patients to stop effective drug therapy and return to surgical options, thereby decreasing sustained drug sales volume.

Additionally, these safety profiles make it difficult to economically justify high-cost branded treatments. Insurance providers and payers apply strict reimbursement standards, showing reluctance to cover expensive medications that offer only temporary symptom relief due to mandatory usage caps, which limits widespread adoption. The consequence of these restrictions is highlighted by the ongoing economic burden of the condition; the Society for Women's Health Research estimated in 2025 that lost work productivity among fibroid patients totaled up to $17.2 billion. This statistic underscores how the market's failure to offer safe, long-term pharmacological management leaves a significant clinical and economic void, ultimately stalling the sector's overall expansion.

Market Trends

The treatment landscape is being fundamentally reshaped by the integration of combination therapies designed to mitigate hypoestrogenic side effects, thereby overcoming the safety constraints of earlier hormonal treatments. Although Gonadotropin-Releasing Hormone (GnRH) antagonists successfully reduce fibroid size, their long-term application has historically been limited by the risk of bone mineral density loss; to counter this, developers are commercializing fixed-dose regimens that include "add-back" therapy-usually norethindrone acetate and estradiol-to keep estrogen levels within a range that preserves bone health without reducing efficacy. This advancement enables longer treatment durations, which drives adoption for chronic management, as evidenced by Sumitomo Pharma's 'Summary of Consolidated Financial Results for the Year Ended March 31, 2025' from May 2025, which reported a 32% year-over-year revenue increase for the combination therapy Myfembree in fiscal year 2024.

Concurrently, there is an accelerating paradigm shift toward utilizing pharmacological interventions as first-line therapy, as providers and patients increasingly move away from invasive surgeries like hysterectomies. This transition is driven by the rising availability of effective oral treatments that offer a "uterine-sparing" alternative, meeting the needs of women who wish to avoid the complications and recovery times associated with surgery. Clinical guidelines are adapting to endorse medical management as a primary step rather than "watchful waiting" or a precursor to surgery, which expands the target patient population; this structural change is reflected in sector performance, such as Gedeon Richter's 'Q4/FY2024 Earnings Report' from February 2025, where the Women's Healthcare division posted a 12% revenue rise in 2024, indicating the growing role of pharmaceutical management in standard care.

Key Market Players

• Myovant Sciences Ltd
• Pfizer Inc
• Abbvie Inc
• Ferring BV
• AstraZeneca
• Bayer AG
• Amring Pharmaceuticals Inc
• Watson Pharma Pvt Ltd

Report Scope

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Fibroid Treatment Drugs Market, By Drug Class

• Gonadotropin-Releasing Hormone (Gnrh) Agonists
• Gonadotropin-Releasing Hormone (Gnrh) Antagonists
• Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
• Non-Hormonal Medications
• Others

Uterine Fibroid Treatment Drugs Market, By Type

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User

• Hospital Pharmacies
• Retail Pharmacies
• Others

Uterine Fibroid Treatment Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroid Treatment Drugs Market.

Available Customizations:

Global Uterine Fibroid Treatment Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Fibroid Treatment Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
  • 5.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
  • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Uterine Fibroid Treatment Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Uterine Fibroid Treatment Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Uterine Fibroid Treatment Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End User

7. Europe Uterine Fibroid Treatment Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Uterine Fibroid Treatment Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Uterine Fibroid Treatment Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Uterine Fibroid Treatment Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Uterine Fibroid Treatment Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Uterine Fibroid Treatment Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Myovant Sciences Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc
• 15.3. Abbvie Inc
• 15.4. Ferring BV
• 15.5. AstraZeneca
• 15.6. Bayer AG
• 15.7. Amring Pharmaceuticals Inc
• 15.8. Watson Pharma Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer